Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis  Jean-Pierre Pelletier, MD  Osteoarthritis and Cartilage  Volume 12, Pages 63-68 (January 2004) DOI: 10.1016/j.joca.2003.09.014

Fig. 1 Global interaction of catabolic pathways in osteoarthritic tissues, which are responsible for the structural changes of the disease. (Reproduced with permission. Henrotin Y, Reginster J-Y. Le cartilage articulaire peut-il se régénérer? Le généraliste 1988;415:11.) Osteoarthritis and Cartilage 2004 12, 63-68DOI: (10.1016/j.joca.2003.09.014)

Fig. 2 Schematic representation of the role of the inducible form of nitric oxide synthase (iNOS) and nitric oxide (NO) in the pathophysiology of osteoarthritis. (Reproduced from Arthritis and Allied Conditions. A Textbook of Rheumatology, 14th edition, Baltimore, MD: Lippincott, Williams & Wilkins, 2000; pp.2195–2215, Figure 110.3, with permission from Lippincott, Williams & Wilkins.) Osteoarthritis and Cartilage 2004 12, 63-68DOI: (10.1016/j.joca.2003.09.014)

Fig. 3 Schematic representation of the mechanisms involved in the remodeling of osteoarthritic subchondral bone and possible interaction with cartilage. (Reproduced from JY Reginster, JP Pelletier, J Martel-Pelletier, Y Henrotin, Eds. Osteoarthritis: Clinical and Experimental Aspects, Heidelberg, Germany: Springer-Verlag, 1999, pp. 156–187, Fig. 2, with permission from Springer-Verlag GmbH & Co. KG.) Osteoarthritis and Cartilage 2004 12, 63-68DOI: (10.1016/j.joca.2003.09.014)